You are here

Curetis’ Subsidiary Ares Genetics and QIAGEN Enter into Bioinformatics Partnership to Fight Antimicrobial Resistance

Vienna, Austria, Holzgerlingen, Germany, and Amsterdam, The Netherlands, February 18, 2019, 22:00 CET - Curetis N.V. (the "Company" and together with its subsidiaries "Curetis"), a developer of next-level molecular diagnostic solutions, today announced that its wholly-owned subsidiary Ares Genetics GmbH (Vienna, Austria) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) have entered into a strategic licensing agreement for ARESdb and AREStools in the area of antimicrobial resistance (AMR) research.
Monday, February 18, 2019 - 16:05